NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Data completeness
6/8 — Strong
Priority Review
GIAPREZA (angiotensin ii) by Immuno Technologies is 12. Approved for septic shock. First approved in 2017.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GIAPREZA (angiotensin II) is a synthetic vasoconstrictor approved for septic shock, a life-threatening condition of severe infection and organ dysfunction. It works by binding to angiotensin II receptor type 1 on vascular smooth muscle cells, triggering vasoconstriction and increased aldosterone release to raise blood pressure. The drug represents a novel mechanism in critical care hemodynamics, distinct from traditional catecholamine-based vasopressors.
Peak10.7 years to LOE
Product is at peak commercial stage with established ICU presence; brand teams are likely focused on market penetration and retention against growing competitive pressure.
Mechanism of Action
12.1. Mechanism of Action Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein-coupled angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates…
Pharmacologic Class:
Vasoconstrictor
Indications (1)
Clinical Trials (9)
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
Started Jan 2026
15 enrolled
Liver Cancer (Locally Advanced or Metastatic)Liver Cancer Adult
Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension
Started Sep 2025
30 enrolled
Vasodilatory Shock
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
Started Jul 2024
214 enrolled
Vasodilatory Shock
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
Started May 2009
123 enrolled
Heart Failure
Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)
Started Dec 2004
25 enrolled
Hypertension
Worked on GIAPREZA at Immuno Technologies? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.